Ranbaxy Could Lose Diovan Generic Exclusivity In Mylan U.S. Court Suit
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories is watching closely a suit filed by Mylan against U.S. FDA for denying its application for a generic of the Novartis hypertension drug Diovan (valsartan) to compete with Ranbaxy's generic.